Technical Analysis for INSY - Insys Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 6.09 3.92% 0.23
INSY closed up 3.92 percent on Friday, December 8, 2017, on 1.68 times normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical INSY trend table...

Date Alert Name Type % Chg
Dec 8 50 DMA Resistance Bearish 0.00%
Dec 8 Shooting Star Candlestick Bearish 0.00%
Dec 8 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Dec 8 New Uptrend Bullish 0.00%
Dec 8 Wide Bands Range Expansion 0.00%
Dec 8 Above Upper BB Strength 0.00%
Dec 7 1,2,3 Retracement Bearish Bearish Swing Setup 3.92%
Dec 7 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.92%
Dec 7 Weak + Overbought Other 3.92%
Dec 7 BB Squeeze Ended Range Expansion 3.92%

Older signals for INSY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray, a single-use product for the treatment of breakthrough cancer pain; and Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution, which completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting, and appetite stimulation in AIDS patients. It also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid liposomal, which is in Phase II clinical development stage to enhance efficacy and reduce paclitaxel-related side effects. The company was founded in 2002 and is based in Phoenix, Arizona.
Is INSY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.02
52 Week Low 4.1
Average Volume 803,506
200-Day Moving Average 9.9101
50-Day Moving Average 6.4052
20-Day Moving Average 5.3125
10-Day Moving Average 5.416
Average True Range 0.4276
ADX 40.69
+DI 24.37
-DI 14.69
Chandelier Exit (Long, 3 ATRs ) 5.2972
Chandelier Exit (Short, 3 ATRs ) 6.1828
Upper Bollinger Band 5.7837
Lower Bollinger Band 4.8413
Percent B (%b) 1.33
BandWidth 17.739294
MACD Line -0.1495
MACD Signal Line -0.3266
MACD Histogram 0.1771
Fundamentals Value
Market Cap 442.72 Million
Num Shares 72.7 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -27.68
Price-to-Sales 2.18
Price-to-Book 1.57
PEG Ratio -0.62
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.08
Resistance 3 (R3) 7.13 6.86 6.92
Resistance 2 (R2) 6.86 6.60 6.83 6.86
Resistance 1 (R1) 6.47 6.45 6.67 6.42 6.80
Pivot Point 6.20 6.20 6.29 6.17 6.20
Support 1 (S1) 5.81 5.94 6.01 5.76 5.38
Support 2 (S2) 5.54 5.79 5.51 5.32
Support 3 (S3) 5.15 5.54 5.27
Support 4 (S4) 5.10